Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders

Scandinavian Journal of Immunology

Volumn 71, Issue 3, 2010, Pages 125-133

  Barabas, Arpad Z ^a   Cole, Chad D ^b   Barabas, Arpad D ^a   Graeff, Richard M ^c   Lafreniere, Rene ^a   Weir, Donald M ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IA ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE COURSE; DOWN REGULATION; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; MODIFIED VACCINATION TECHNIQUE; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENICITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; CANCER VACCINES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KIDNEY DISEASES; RATS; VACCINATION;

EID: 77449128483     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02360.x     Document Type: Review

References (92)

1. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Pathogenic and nonpathogenic autoimmune events - the good and/or the bad? In : Dubois Q, ed. Autoantibodies Research Progress. Hauppauge NY : Nova Science Publishers, Inc., 2008 : 9 18, ISBN: 978-1-60456-108-1.
2. Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. A vaccination technique to combat presently untreatable chronic ailments. BioProcessing J 2007 6 : 12 8.
3. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001 345 : 340 350.
4. Sinha AA, Lopez MT, McDevitt HO. Autoimmune diseases: the failure of self tolerance. Science 1990 248 : 1380 1388.
5. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity - friends or foes? Trends Immunol 2009 30 : 409 414.
6. Shoenfeld Y, Zandman-Goddard G, Stojanovich L et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases - 2008. Isr Med Assoc J 2008 10 : 8 12. (Pubitemid 351649455)
7. Butcher G. Autoimmunity and malaria. Trends Parasitol 2008 24 : 291 292.
8. Leibowitz U, Antonovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966 29 : 60 8.
9. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol 2004 85 : 277 285.
10. Ebringer A, Thorpe C, Pirt J, Wilson C, Cunningham P, Ettelaie C. Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens? Environ Health Perspect 1997 105 : 1172 1174.
11. Ebringer A. Molecular mimicry as the basis of a new theory of autoimmunity. In : Zouali M, ed. Frontiers in Autoimmunity: Fundamental Aspects and Clinical Perspectives. Amsterdam : IOS Press, 2003 : 79 99, ISBN: 978-1586033613.
12. Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP. Production of the nephritic syndrome in rat by Freund's adjuvant and rat kidney suspension. Proc Soc Exp Biol Med 1959 100 : 660 664.
13. Wucherpfennig KW. Structural basis of molecular mimicry. J Autoimmun 2001 16 : 293 302.
14. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 1991 12 : 154 159.
15. Weir DM, Pinckard RN, Elson CJ, Suckling DE. Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol 1966 1 : 433 442.
16. Weir DM, Pinckard RN. Failure to induce tolerance to rat tissue antigens. Immunology 1967 13 : 373 380.
17. Manson JJ, Mauri C, Ehrenstein MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 2005 26 : 425 432.
18. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998 188 : 2313 2320.
19. Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 2005 35 : 252 260.
20. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA 2000 97 : 1184 1189.
21. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol 2003 84 : 245 258.
22. Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994 266 : 810 813.
23. Rich MW. Drug-induced lupus. The list of culprits grows. Postgrad Med 1996 100 : 299 308.
24. Totoritis MC, Rubin RL. Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad Med 1985 78 : 149 161.
25. Yung R, Chang S, Hemati N, Johnson K, Richardson B. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 1997 40 : 1436 1443.
26. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am 1994 20 : 61 86.
27. Yung RL, Johnson KJ, Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest 1995 73 : 746 759.
28. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005 435 : 612 619.
29. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001 61 : 5137 5144.
30. Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. New vaccination technology for endogenous antigen-derived ailments. IDrugs 2008 11 : 111 115.
31. Cope AP, Feldmann M. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr Opin Immunol 2004 16 : 780 786.
32. Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009 5 : 433 441.
33. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 83 : 435 445.
34. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 353 : 1673 1684.
35. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 344 : 783 792.
36. Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000 6 : 1167 1175.
37. Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999 73 : 153 264.
38. Genain CP, Abel K, Belmar N et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996 274 : 2054 2057.
39. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993 341 : 927 928.
40. Peakman M, Dayan CM. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire? Immunology 2001 104 : 361 366.
41. Trentham DE, Dynesius-Trentham RA, Orav EJ et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993 261 : 1727 1730.
42. Bellmann K, Kolb H, Rastegar S, Jee P, Scott FW. Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats. Diabetologia 1998 41 : 844 847.
43. Fox RJ, Ransohoff RM. New directions in MS therapeutics: vehicles of hope. Trends Immunol 2004 25 : 632 636.
44. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol 2004 85 : 321 334.
45. Alousi MA, Post RS, Heymann W. Experimental autoimmune nephrosis in rats. Morphogenesis of the glomerular lesion: immunohistochemical and electron microscopic studies. Am J Pathol 1969 54 : 47 71.
46. Mokhtarian F, Zhang Z, Shi Y, Gonzales E, Sobel RA. Molecular mimicry between a viral peptide and a myelin oligodendrocyte glycoprotein peptide induces autoimmune demyelinating disease in mice. J Neuroimmunol 1999 95 : 43 54.
47. Orbach H, Shoenfeld Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 2007 6 : 261 266.
48. Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008 8 : 124 128.
49. Lenz DC, Lu L, Conant SB et al. A Chlamydia pneumoniae-specific peptide induces experimental autoimmune encephalomyelitis in rats. J Immunol 2001 167 : 1803 1808.
50. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005 38 : 235 245.
51. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int 2006 56 : 181 190.
52. Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol 2006 13 : 17 24.
53. Pinckard RN, Weir DM. Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin Exp Immunol 1966 1 : 33 43.
54. Weir DM. Immunological reaction after tissue injury. Lancet 1964 1 : 749 750.
55. Weir DM. The immune response after tissue injury. Pathol Eur 1966 1 : 108 118.
56. Weir DM. The immunologicial consequences of cell death. Lancet 1967 2 : 1071 1073.
57. Zwart B, Ciurana C, Rensink I, Manoe R, Hack CE, Aarden LA. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity 2004 37 : 95 102. (Pubitemid 38594273)
58. Barabas AZ, Cole CD, Barabas AD et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol 2004 85 : 201 212.
59. Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med 2000 191 : 1253 1258.
60. Lowrie DB. DNA vaccines for therapy of tuberculosis: where are we now? Vaccine 2006 24 : 1983 1989.
61. Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine 2007 25 (Suppl. 2 B72 88.
62. Lollini PL, Forni G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother 2002 51 : 409 416.
63. Milstein C, Waldmann H. Optimism after much pessimism: what next? Curr Opin Immunol 1999 11 : 589 591.
64. Nepom GT. Therapy of autoimmune diseases: clinical trials and new biologics. Curr Opin Immunol 2002 14 : 812 815.
65. Pellegrini M, Calzascia T, Elford AR et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009 15 : 528 536.
66. Andre FE. Vaccinology: past achievements, present roadblocks and future promises. Vaccine 2003 21 : 593 595.
67. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005 206 : 232 259.
68. Garren H, Robinson WH, Krasulova E et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008 63 : 611 620.
69. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005 4 : 526 531.
70. Quintana FJ, Carmi P, COHEN IR. DNA vaccination with heat shock protein 60 inhibits cyclophosphamide-accelerated diabetes. J Immunol 2002 169 : 6030 6035. (Pubitemid 35291711)
71. Zhang J. T cell vaccination as an immunotherapy for autoimmune diseases. Cell Mol Immunol 2004 1 : 321 327.
72. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol 2002 14 : 517 521.
73. Radbruch A, Muehlinghaus G, Luger EO et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006 6 : 741 750.
74. Barabas AZ, Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev 2005 4 : 565 570.
75. Liu Q, Kriksunov IA, Graeff R, Munshi C, Lee HC, Hao Q. Crystal structure of human CD38 extracellular domain. Structure 2005 13 : 1331 1339.
76. Munshi CB, Fryxell KB, Lee HC, Branton WD. Large-scale production of human CD38 in yeast by fermentation. Methods Enzymol 1997 280 : 318 330.
77. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics 2007 1 : 59 68.
78. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann N Y Acad Sci 2007 1110 : 619 629.
79. Klaus GG. The generation of memory cells. II. Generation of B memory cells with preformed antigen-antibody complexes. Immunology 1978 34 : 643 652.
80. Kunkl A, Klaus GG. The generation of memory cells. IV. Immunization with antigen-antibody complexes accelerates the development of B-memory cells, the formation of germinal centres and the maturation of antibody affinity in the secondary response. Immunology 1981 43 : 371 378.
81. Nie X, Basu S, Cerny J. Immunization with immune complex alters the repertoire of antigen-reactive B cells in the germinal centers. Eur J Immunol 1997 27 : 3517 3525.
82. Stoner RD, Terres G. Enhanced antitoxin responses in irradiated mice elicited by complexes of tetanus toxoid and specific antibody. J Immunol 1963 91 : 761 770.
83. Stoner RD, Terres G, Hess MW. Early and enhanced antioxin responses elicited with complexes of tetanus toxoid and specific mouse and human antibodies. J Infect Dis 1975 131 : 230 238.
84. Terres G, Wolins W. Enhanced sensitization in mice by simultaneous injection of antigen and specific rabbit antiserum. Proc Soc Exp Biol Med 1959 102 : 632 635.
85. Terres G, Wolins W. Enhanced immunological sensitization of mice by the simultaneous injection of antigen and specific antiserum. I. Effect of varying the amount of antigen used relative to the antiserum. J Immunol 1961 86 : 361 368.
86. Terres G, Stoner RD. Specificity of enhanced immunological sensitization of mice following injections of antigens and specific antisera. Proc Soc Exp Biol Med 1962 109 : 88 91.
87. Terres G, Morrison SL, Habicht GS, Stoner RD. Appearance of an early "primed state" in mice following the concomitant injections of antigen and specific antiserum. J Immunol 1972 108 : 1473 1481.
88. Haddad EE, Whitfill CE, Avakian AP et al. Efficacy of a novel infectious bursal disease virus immune complex vaccine in broiler chickens. Avian Dis 1997 41 : 882 889.
89. Jeurissen SH, Janse EM, Lehrbach PR, Haddad EE, Avakian A, Whitfill CE. The working mechanism of an immune complex vaccine that protects chickens against infectious bursal disease. Immunology 1998 95 : 494 500.
90. Whitfill CE, Haddad EE, Ricks CA et al. Determination of optimum formulation of a novel infectious bursal disease virus (IBDV) vaccine constructed by mixing bursal disease antibody with IBDV. Avian Dis 1995 39 : 687 699.
91. Wen YM. Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections. Expert Opin Biol Ther 2009 9 : 285 291.
92. Delaleu N, Peck AB. Autoimmunity: limited progress for the patient, despite decades of research. Scand J Immunol 2009 70 : 411 414.